StreetInsider.com News Articles

Tigermed Receives MSCI ESG AAA Rating

Mon, 18 Aug 2025 23:15:00 -0400

HANGZHOU, China, Aug. 18, 2025 /PRNewswire/ -- Tigermed is proud to announce that it has been awarded an MSCI Environmental, Social, and Governance (ESG) Rating of AAA, the highest rating in the industry. This recognition underscores our commitment to excellence in ESG practices, positioning us as a leader in sustainable business performance.

MSCI's AAA rating is reserved for companies that demonstrate superior ESG performance and strong resilience to long-term risks. It reflects Tigermed's consistent efforts to integrate ESG principles into our core operations and strategic decision-making.

Environmental:
Tigermed has set science-based

Tigermed Receives MSCI ESG AAA Rating

Mon, 18 Aug 2025 23:15:00 -0400

Environmental:
Tigermed has set science-based

Tigermed Receives MSCI ESG AAA Rating

Mon, 18 Aug 2025 23:15:00 -0400

Environmental:
Tigermed has set science-based

Tigermed Receives MSCI ESG AAA Rating

Mon, 18 Aug 2025 23:15:00 -0400

Environmental:
Tigermed has set science-based

Tigermed Receives MSCI ESG AAA Rating

Mon, 18 Aug 2025 23:15:00 -0400

Environmental:
Tigermed has set science-based

Tigermed Receives MSCI ESG AAA Rating

Mon, 18 Aug 2025 23:15:00 -0400

Environmental:
Tigermed has set science-based

Tigermed Receives MSCI ESG AAA Rating

Mon, 18 Aug 2025 23:15:00 -0400

Environmental:
Tigermed has set science-based

Tigermed Receives MSCI ESG AAA Rating

Mon, 18 Aug 2025 23:15:00 -0400

Environmental:
Tigermed has set science-based

Tigermed completes acquisition of Japanese imaging CRO Micron

Tue, 29 Jul 2025 01:37:54 -0400

Tigermed (300347.SZ/3347.HK) announced the completion of its acquisition of Micron Inc., a Tokyo-based contract research organization specializing in medical imaging and clinical trial services.

Founded in 2005, Micron employs over 160 people and operates as Japan's first imaging CRO. The company has served more than 250 clients and contributed to the approval of over 40 drugs during its nearly two decades of operation. Micron maintains offices in Tokyo, Osaka, and Nagoya.

The acquired company focuses on medical imaging expertise and clinical research services, including monitoring, quality control, imaging core lab operations, image analysis, and centralized imaging review. Micron also serves as an

Tigermed completes acquisition of Japanese imaging CRO Micron

Tue, 29 Jul 2025 01:37:54 -0400

Tigermed (300347.SZ/3347.HK) announced the completion of its acquisition of Micron Inc., a Tokyo-based contract research organization specializing in medical imaging and clinical trial services.

Tigermed completes acquisition of Japanese imaging CRO Micron

Tue, 29 Jul 2025 01:37:54 -0400

Tigermed (300347.SZ/3347.HK) announced the completion of its acquisition of Micron Inc., a Tokyo-based contract research organization specializing in medical imaging and clinical trial services.

Tigermed completes acquisition of Japanese imaging CRO Micron

Tue, 29 Jul 2025 01:37:54 -0400

Tigermed (300347.SZ/3347.HK) announced the completion of its acquisition of Micron Inc., a Tokyo-based contract research organization specializing in medical imaging and clinical trial services.

Tigermed Completes Acquisition of Japanese CRO Micron

Tue, 29 Jul 2025 01:18:00 -0400

HANGZHOU, China and TOKYO, July 29, 2025 /PRNewswire/ -- Tigermed (300347.SZ / 3347.HK), a leading global provider of clinical research solutions across the full lifecycle of global biopharmaceutical and medical device products, today announces the completion of its acquisition of CRO company Micron,Inc.

Founded in 2005 and headquartered in Tokyo, Micron is a Japan-based Contract Research Organization (CRO) focusing in medical imaging and clinical trial services with over 160 employees. Micron brings nearly two decades of

Tigermed Completes Acquisition of Japanese CRO Micron

Tue, 29 Jul 2025 01:18:00 -0400

Tigermed Completes Acquisition of Japanese CRO Micron

Tue, 29 Jul 2025 01:18:00 -0400

Tigermed Completes Acquisition of Japanese CRO Micron

Tue, 29 Jul 2025 01:18:00 -0400

Tigermed Completes Acquisition of Japanese CRO Micron

Tue, 29 Jul 2025 01:18:00 -0400

Tigermed Completes Acquisition of Japanese CRO Micron

Tue, 29 Jul 2025 01:18:00 -0400

Tigermed Completes Acquisition of Japanese CRO Micron

Tue, 29 Jul 2025 01:18:00 -0400

Tigermed Completes Acquisition of Japanese CRO Micron

Tue, 29 Jul 2025 01:18:00 -0400

Tigermed Reports Full Year 2024 Results

Thu, 27 Mar 2025 06:48:00 -0400

HANGZHOU, China, March 27, 2025 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annual results for the year ended December 31, 2024 (the "Reporting Period").

This press release is for information purposes only and is not intended to provide any representation, in whole or in part, of the relevant matters. Please refer to the 2024 annual results announcement and other relevant announcements published on the websites

Tigermed Reports Full Year 2024 Results

Thu, 27 Mar 2025 06:48:00 -0400

HANGZHOU, China, March 27, 2025 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annual results for the year ended December 31, 2024 (the "Reporting Period").

This press release is for information purposes only and is not intended to provide any representation, in whole or in part, of the relevant matters. Please refer to the 2024 annual results announcement and other relevant announcements published on the websites

Tigermed Reports Full Year 2024 Results

Thu, 27 Mar 2025 06:48:00 -0400

HANGZHOU, China, March 27, 2025 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annual results for the year ended December 31, 2024 (the "Reporting Period").

This press release is for information purposes only and is not intended to provide any representation, in whole or in part, of the relevant matters. Please refer to the 2024 annual results announcement and other relevant announcements published on the websites

Tigermed Reports Full Year 2024 Results

Thu, 27 Mar 2025 06:48:00 -0400

HANGZHOU, China, March 27, 2025 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annual results for the year ended December 31, 2024 (the "Reporting Period").

This press release is for information purposes only and is not intended to provide any representation, in whole or in part, of the relevant matters. Please refer to the 2024 annual results announcement and other relevant announcements published on the websites

Tigermed Reports Full Year 2024 Results

Thu, 27 Mar 2025 06:48:00 -0400

HANGZHOU, China, March 27, 2025 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annual results for the year ended December 31, 2024 (the "Reporting Period").

This press release is for information purposes only and is not intended to provide any representation, in whole or in part, of the relevant matters. Please refer to the 2024 annual results announcement and other relevant announcements published on the websites